NEW YORK (GenomeWeb) – Freenome and Biognosys today announced a partnership aimed at improving the early detection of cancer and precision oncology.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test, the partners said in a statement. Freenome's artificial intelligence platform decodes cell-free biomarker patterns to detect cancer by analyzing fragments of cfDNA and cfRNA that are released into the bloodstream when cancer destroys immune and other cells in the tumor environment.
Financial and other terms of the deal were not disclosed.
"Changes in protein expression can be either direct or surrogate markers for emerging disease processes in the body," Freenome CSO Imran Haque said in a statement. "Working with Biognosys gives us a distinct and complementary type of information to use alongside our genomic sequencing data, which in turn may improve the performance of our tests."
Last month, Institut Curie said it would test the efficacy of Freenome's platform for studying changings in circulating cfDNA to predict patient response to immune-oncology treatments.